In Q2 of fiscal 2026, the quarter ended Jul 4, 2026, Usana Health Sciences, Inc. reported revenue of $223.3 million, down 5.3% from the same quarter a year earlier. It recorded a net loss of $21.4 million. The operating loss came to $20.0 million, an operating margin of -9.0%. Diluted earnings per share were -$1.16.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jul 4, 2026
|
Q2 FY2026
Jul 4, 2026
|
Q1 FY2026
Apr 4, 2026
|
Q4 FY2025
Jan 3, 2026
|
Q3 FY2025
Sep 27, 2025
|
Q2 FY2025
Jun 28, 2025
|
Q1 FY2025
Mar 29, 2025
|
Q3 FY2024
Sep 28, 2024
|
Q2 FY2024
Jun 29, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
913
|
223
-5.3%
|
250
+0.3%
|
226
|
214
+6.7%
|
236
+10.8%
|
250
+9.5%
|
200
-6.2%
|
213
-10.6%
|
| Cost of revenue |
206
|
48
-3.7%
|
59
+13.3%
|
49
|
49
+24.3%
|
50
+24.4%
|
52
+21.8%
|
39
-7.7%
|
40
-6.9%
|
| Gross profit |
707
|
175
-5.8%
|
191
-3.2%
|
177
|
165
+2.4%
|
186
+7.6%
|
197
+6.7%
|
161
-5.8%
|
173
-11.5%
|
| Selling, general and administrative |
335
|
82
+0.5%
|
88
-3.5%
|
78
|
86
+40.2%
|
82
+27.3%
|
91
+42.2%
|
61
-3.2%
|
64
-5.5%
|
| Operating income |
-1
|
-20
-219.6%
|
14
-11.5%
|
4
|
1
-92.2%
|
17
-6.3%
|
16
-36.5%
|
16
-11.4%
|
18
-26.9%
|
| Interest income |
2
|
1
-3.9%
|
0
-39.6%
|
0
|
1
-81.6%
|
1
-77.6%
|
1
-73.0%
|
3
+15.0%
|
3
+24.2%
|
| Interest expense |
0
|
0
-100.0%
|
0
-41.6%
|
0
|
0
+0.0%
|
0
+407.8%
|
0
|
0
|
0
|
| Other non-operating income (expense) |
2
|
1
-71.2%
|
1
+84.4%
|
-0
|
0
+147.7%
|
2
+598.3%
|
1
+506.5%
|
-0
-136.8%
|
-0
-252.4%
|
| Pretax income |
3
|
-19
-200.4%
|
15
-7.6%
|
4
|
2
-90.4%
|
19
-6.9%
|
17
-38.3%
|
19
-9.4%
|
20
-24.6%
|
| Income tax |
32
|
9
+8.1%
|
9
+14.2%
|
6
|
8
+5.7%
|
8
-14.3%
|
7
-29.6%
|
8
-12.9%
|
10
+2.7%
|
| Net income |
-22
|
-21
-321.5%
|
8
-20.1%
|
-2
|
-7
-161.5%
|
10
-7.4%
|
9
-43.1%
|
11
-6.5%
|
10
-39.7%
|
| Basic EPS |
-1.21
|
-1.16
-323.1%
|
0.41
-16.3%
|
-0.10
|
-0.36
-164.3%
|
0.52
-5.5%
|
0.49
-43.0%
|
0.56
-5.1%
|
0.55
-38.2%
|
| Diluted EPS |
-1.20
|
-1.16
-323.1%
|
0.41
-16.3%
|
-0.10
|
-0.36
-164.3%
|
0.52
-3.7%
|
0.49
-43.0%
|
0.56
-5.1%
|
0.54
-39.3%
|
| Weighted average shares, basic |
18
|
18
-0.1%
|
18
-3.4%
|
18
|
18
-4.1%
|
19
-2.9%
|
19
-0.7%
|
19
-0.9%
|
19
-1.3%
|
| Weighted average shares, diluted |
18
|
18
-0.3%
|
18
-3.5%
|
18
|
18
-4.1%
|
19
-3.3%
|
19
-1.1%
|
19
-1.5%
|
19
-1.4%
|
| Other measures | |||||||||
| Depreciation and amortization |
32
|
8
-0.9%
|
8
-0.7%
|
9
|
8
+121.9%
|
8
+103.1%
|
8
+164.1%
|
4
+9.1%
|
4
+18.4%
|
| EBITDA |
31
|
-12
-150.4%
|
22
-7.7%
|
12
|
9
-52.3%
|
24
+13.0%
|
24
-13.7%
|
19
-8.2%
|
22
-21.6%
|
| Interest coverage |
-2.62x
|
—
|
57.81x
|
31.05x
|
24.98x
|
64.55x
|
38.13x
|
318.39x
|
349.80x
|
| Margins | |||||||||
| Gross margin |
77.45%
|
78.35%
|
76.25%
|
78.16%
|
77.15%
|
78.72%
|
78.98%
|
80.39%
|
81.05%
|
| Operating margin |
-0.12%
|
-8.96%
|
5.54%
|
1.69%
|
0.57%
|
7.09%
|
6.28%
|
7.79%
|
8.38%
|
| Pretax margin |
0.28%
|
-8.46%
|
6.18%
|
1.85%
|
0.84%
|
7.98%
|
6.71%
|
9.29%
|
9.49%
|
| Profit margin |
-2.43%
|
-9.58%
|
3.00%
|
-0.78%
|
-3.05%
|
4.09%
|
3.77%
|
5.30%
|
4.90%
|
| EBITDA margin |
3.43%
|
-5.52%
|
8.85%
|
5.47%
|
4.28%
|
10.37%
|
9.62%
|
9.57%
|
10.17%
|
| Effective tax rate |
1,253.35%
|
—
|
55.00%
|
138.19%
|
471.35%
|
44.50%
|
44.50%
|
43.00%
|
48.36%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- USNA (NYSE)
- Fiscal year ends
- January 3
- Incorporated in
- UT
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Accelerated filer
- SEC CIK
- 896264
- Former names
- USANA INC (until Apr 27, 2000)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.